Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company dedicated to advancing treatments for allergic and immunological diseases, has announced its partnership with Ypsomed for developing an autoinjector for STAR-0215. This collaboration aims to enhance the delivery system for STAR-0215, a therapy designed for hereditary angioedema.
Astria Therapeutics Partners with Ypsomed for STAR-0215 Autoinjector Development
Astria Therapeutics, Inc. (NASDAQ: ATXS) is excited to announce its collaboration with Ypsomed for the development of an autoinjector for STAR-0215. John Ruesch, Senior Vice President of Pharmaceutical Sciences and Technical Operations, emphasized that STAR-0215 aims to provide patients with flexible treatment options, including infrequent administration every three to six months. The partnership with Ypsomed, known for its expertise in injection systems, will help realize this vision by creating an autoinjector that balances effective protection against hereditary angioedema (HAE) attacks with minimal treatment burden.
Pending regulatory approval, STAR-0215 will be available in both the Ypsomed YpsoMate autoinjector and a pre-filled syringe, giving patients the choice of the administration method that best suits their needs. The autoinjector is expected to offer ease of use, needle shielding, and a proprietary formulation for a quick and low-pain injection experience.
About Astria Therapeutics
Astria Therapeutics is dedicated to developing transformative therapies for allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody targeting plasma kallikrein for hereditary angioedema. We are also advancing STAR-0310, a monoclonal antibody OX40 antagonist, in preclinical development for atopic dermatitis.
About YpsoMate
The YpsoMate is a user-friendly autoinjector featuring a two-step process. After removing the cap and pressing the device against the skin, patients receive visual and audible cues to guide the injection. The safety mechanism shields the needle before and after use to prevent needle-stick injuries and ensure a needle-free experience. YpsoMate also aligns with Ypsomed’s NetZero Program, reflecting a commitment to sustainability.
About Ypsomed AG
Ypsomed is a leader in developing and manufacturing self-medication systems, celebrating its 40th anniversary in 2024. Known for innovation and technology, Ypsomed is a trusted partner for pharmaceutical and biotech companies, offering pens, autoinjectors, and pump systems for medication delivery. Ypsomed operates under the mylife Diabetescare and Ypsomed Delivery Systems brands, with a global presence in production, distribution, and support. The company is headquartered in Burgdorf, Switzerland, and employs around 2,500 people worldwide.
